



Grants Awarded through Expression of Interest Process 1 December 2024 to 30 September 2025

ANTIVIRAL STRATEGIES	
Prof Gilda Tachedjian	Towards a bespoke gel to decrease neovaginal inflammation and HIV acquisition in transgender women
Dr Paula Cevaál	Leveraging novel CRISPR and lipid nanoparticle technologies to permanently silence HIV
A/Prof Thomas Tu	Novel curative therapies targeting cells that maintain HBV covalently closed circular DNA
DIAGNOSTICS/PROGNOSTICS	
Dr Melissa John	Improving access to a novel molecular assay for enhanced HTLV diagnosis, surveillance and proviral load monitoring in Australia
Prof Peter Revill	Development of a Point of Care assay for the Hepatitis B e antigen
Dr Kazuo Suzuki	Investigation of cell associated HIV-1 RNA transcripts in viral reservoir for cure research
Prof Mark Douglas	Measuring Hepatitis B Virus evolutionary speed as a novel prognostic biomarker for clinical outcomes
VACCINES/PREVENTION AND IMMUNOTHERAPY	
Dr Bruce Wines	Stellabody® enhancement of HIV therapeutic antibodies
Dr Marcel Doerflinger	RNAi therapy to target host cell death to mitigate HTLV-1 infection in vivo
Prof Tony Cunningham	Targeting latent HIV by novel combination immunotherapy with IFN α 8 and CAR T-cells